Pyxis Oncology vs Whitehawk Therapeutics
PYXS and WHWK side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How PYXS and WHWK compare
Whitehawk Therapeutics is the larger company, worth 1.2 times as much as Pyxis Oncology ($185M against $151M).
Whitehawk Therapeutics scores higher on the StockData Score (8 against 5 for Pyxis Oncology), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | PYXS | WHWK |
|---|---|---|
| Size and price | ||
| Market cap | $151M | $185M |
| Share price | $1.81 | $3.24 |
| Change, 1 year | −45.3% | 31.7% |
| Change, 5 years | −85.0% | −88.2% |
| Beta (5Y) | 1.62 | 0.77 |
| Employees | 56 | 23 |
| StockData Score | ||
| Total score | 5 | 8 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 0 | 0 |
| Performance score | 0 | 1 (better) |
| Health score | 5 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 13.2× | 1.0× (better) |
| FCF yield | – | −37.5% |
| Growth | ||
| Revenue growth (TTM) | – | −100% |
| Revenue growth, 5Y average | – | −12.6% |
| Profitability | ||
| Return on equity | −179% | −45.0% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 1.34 | 17.38 (better) |
| Altman Z-score | −15.78 | 6.84 (better) |
| Piotroski F-score | 1 | 4 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 40.9% | 75.8% |
| Held by insiders | 20.4% | 49.9% |
| Insider net buying, 12 months | −$107K (better) | −$2.6M |
| Short interest, % of float | 7.4% | 9.5% |
Go deeper
- PYXS stock overview
- PYXS income statement
- PYXS valuation and score
- WHWK stock overview
- WHWK income statement
- WHWK valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.